Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Lantus Medicare Part D Coverage: How to Get Insulin Glargine Covered in 2026

By
Published Updated Last reviewed
7 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug class / Long-acting human insulin analog, injected subcutaneously once daily [2]
  • Prescription status / Prescription-only biologic; Lantus approved April 20, 2000 [4]
  • Products in FDA records / Lantus, Toujeo, Basaglar, Semglee, Rezvoglar [2][3][4][5][6]
  • Concentrations / Lantus and Semglee 100 units/mL; Toujeo 300 units/mL [4][2][5]
  • Lantus biosimilars / Semglee and Rezvoglar; Langlara listed with an April 2026 approval [7]
  • Part D plan information / CMS publishes each year's plan offerings and premiums [1]

The products a plan might list

Lantus and Lantus SoloStar are Sanofi's 100 units/mL products under BLA 021081, approved April 20, 2000 [4]. Toujeo and Toujeo Max SoloStar are Sanofi's 300 units/mL products, approved February 25, 2015 [5]. Basaglar, from Eli Lilly, was approved December 16, 2015 [6]. Semglee (July 2021) and Rezvoglar (December 2021) are FDA-approved biosimilars of Lantus, the reference product, and FDA lists Semglee as the first interchangeable biosimilar insulin [7]. FDA also lists Langlara (insulin glargine-aldy), a Lantus biosimilar, with an April 2026 approval; no Langlara label was found [7]. A biosimilar is approved on data showing it is highly similar to the reference product with no clinically meaningful differences [2].

Lantus and Toujeo are different concentrations

Lantus is 100 units/mL; Toujeo is 300 units/mL, three times as concentrated [4][5]. Unit for unit, Toujeo lowers glucose less than Lantus, so people moving from Lantus to Toujeo should expect to need a higher dose; in trials they used 11% to 18% more basal insulin. Going from Toujeo to Lantus, the Lantus label starts at 80% of the Toujeo dose.

The Semglee and Rezvoglar labels say that changes in insulin strength, manufacturer, type, injection site or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia, and that such changes should be made under close medical supervision with more frequent blood glucose monitoring [2][3]. In type 1 diabetes, these labels say the insulin must be used with short-acting mealtime insulin [2][3].

What the Semglee label says about the drug

The Semglee label says it is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus and is not recommended for the treatment of diabetic ketoacidosis [2]. It lists hypoglycemia as the most common adverse reaction, says severe hypoglycemia can be life-threatening and that the long-acting effect may delay recovery, and contraindicates the product during an episode of hypoglycemia and in people with hypersensitivity to insulin glargine products or an excipient [2]. It also says severe, life-threatening generalized allergy including anaphylaxis can occur, and that prefilled pens, syringes and needles must never be shared between people, even if the needle is changed [2].

Frequently asked questions

Does Medicare Part D cover Lantus in 2026?
CMS's Part D page lists each year's plan offerings and premiums but does not identify coverage for Lantus or any other insulin glargine product, so it does not settle whether a specific 2026 plan covers it [1].
Is there a generic version of Lantus?
Not a traditional generic. Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr) are FDA-approved biosimilars of Lantus, and FDA lists Semglee as the first interchangeable biosimilar insulin [7]. FDA lists Langlara (insulin glargine-aldy), another Lantus biosimilar, with an April 2026 approval [7].
What is the difference between Lantus and Toujeo?
Both contain insulin glargine. Lantus is 100 units/mL and Toujeo is 300 units/mL, three times as concentrated [4][5]. Toujeo has a lower glucose-lowering effect per unit, and in trials people moving from Lantus used 11% to 18% more basal insulin.
What happens if a plan lists a different glargine product?
The Semglee and Rezvoglar labels say that changes in insulin strength, manufacturer, type, injection site or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia, and that such changes call for close medical supervision and more frequent glucose monitoring [2][3].
Is Semglee the same product as Lantus?
Semglee is approved as a biosimilar of Lantus, meaning FDA reviewed it as highly similar to the reference product with no clinically meaningful differences, and FDA lists it as the first interchangeable biosimilar insulin [2][7].

References

  1. Prescription Drug Coverage - General Information | CMS. Prescription Drug Coverage - General Information | CMS
  2. U.S. National Library of Medicine, DailyMed. Semglee insulin glargine-yfgn (Biocon) prescribing information. Semglee insulin glargine-yfgn (Biocon) label
  3. U.S. National Library of Medicine, DailyMed. Rezvoglar KwikPen insulin glargine-aglr (Lilly) prescribing information. Rezvoglar KwikPen insulin glargine-aglr (Lilly) label
  4. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  5. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  6. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  7. Biosimilar Product Information | FDA. Biosimilar Product Information | FDA
Evidence overview for Lantus Medicare Part D Coverage: How to Get Insulin Glargine Covered in 2026